You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 2, 2025

Patent: 10,016,412


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,016,412
Title:TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.
Inventor(s): Spiegel; David (New Haven, CT), Fitzgerald; Kelly (New Haven, CT)
Assignee: YALE UNIVERSITY (New Haven, CT)
Application Number:15/374,272
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Navigating the Complexities of Patent Claims and the US Patent Landscape: A Comprehensive Analysis of US Patent 10,016,412

Introduction

Patent claims are the heart of any patent application, defining the scope of protection for an invention. The landscape of patent law in the United States is complex and constantly evolving, influenced by technological advancements, legal precedents, and regulatory updates. This article will delve into the intricacies of patent claims, using US Patent 10,016,412 as a case study, and explore the broader patent landscape in the US.

Understanding Patent Claims

Definition and Purpose

Patent claims are the specific descriptions of the invention for which the applicant seeks protection. They define the boundaries of the invention and are crucial in determining the scope of the patent[2].

Types of Claims

There are two primary types of claims: independent and dependent claims. Independent claims stand alone and define the invention without reference to other claims. Dependent claims, on the other hand, refer back to and further limit the scope of an independent claim[2].

The Increasing Complexity of Patent Applications

Rise in Patent Applications

The number of patent applications has seen a significant increase over the years. From approximately 100,000 applications per year in the 1960s and 1970s to over 326,000 in 2001, this trend is driven by technological innovation and facilitated by advancements in technology such as word processing and electronic database searching[2].

Growing Number of Claims

Along with the rise in patent applications, the number of claims per application has also increased. Some applications now include hundreds or even thousands of claims, a trend partly driven by legal precedents such as the Festo Corporation v. Shoketsu Kinzoku Kogyo Kabushiki Co. Ltd. case[2].

US Patent 10,016,412: A Case Study

Overview of the Patent

To analyze US Patent 10,016,412 effectively, one must understand the invention it describes and the claims that define its scope. While specific details of this patent are not provided here, a typical analysis would involve examining the independent and dependent claims, the background of the invention, and the detailed description of the invention.

Claim Structure and Hierarchy

The claims in a patent like US 10,016,412 would be structured in a hierarchical manner, with independent claims at the top and dependent claims branching off from them. This hierarchy helps in understanding the scope and limitations of each claim. For instance, a method of claims display, as described in another patent, involves parsing claims into a hierarchical order and compressing them to display only the independent claims initially[2].

Patent Eligibility and the Alice Test

The Alice Framework

The Alice test, established by the Supreme Court in Alice Corp. v. CLS Bank International, is a two-step framework for determining patent eligibility under 35 U.S.C. § 101. The first step involves determining whether the claim is directed to a judicial exception (such as an abstract idea, natural phenomenon, or law of nature). If it is, the second step assesses whether the claim elements, both individually and as an ordered combination, transform the nature of the claim into a patent-eligible application[5].

Application to AI-Related Inventions

The 2024 USPTO guidance update on AI patents clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on whether the claimed invention integrates a judicial exception into a practical application, providing meaningful limits and concrete technological improvements[3].

Anticipation and Prior Art

35 U.S.C. § 102

A claimed invention can be rejected under 35 U.S.C. § 102 if it is anticipated by prior art. For a claim to be anticipated, every element required by the claim must be found in a single prior art reference, either expressly or inherently described[4].

Importance of Novelty

The novelty of an invention is a critical factor in patent law. If an invention is not novel, it cannot be patented. This highlights the need for thorough prior art searches to ensure that the invention is new and non-obvious[4].

Challenges in Patent Classification and Routing

USPTO Oversight

The USPTO faces challenges in overseeing and implementing the patent classification and routing process. A recent audit highlighted the need for improvement in these processes to ensure efficiency and accuracy in handling the increasing volume of patent applications[1].

Impact of Technological Advancements

Automation in Patent Analysis

Technological advancements have led to the development of automated systems for patent analysis. These systems can import, parse, and display patent claims in a hierarchical manner, reducing the amount of information users need to review. This is particularly useful given the increasing complexity and volume of patent applications[2].

Real-World Applications and Practical Utility

Integrating Abstract Ideas into Practical Applications

For a claim to be patent-eligible, it must integrate an abstract idea into a practical application. This involves demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field. For example, a claim that specifies the use of separated audio components in a speech recognition system to enhance accuracy is more likely to be patent-eligible than a claim that merely uses a mathematical model without a practical application[3].

Divergence in Patent Eligibility Analysis

USPTO vs. District Courts

There is sometimes a divergence in how the USPTO and district courts apply the Alice test, leading to conflicting determinations. This highlights the need for consistent and clear guidance on patent eligibility to avoid such discrepancies[5].

Best Practices for Drafting Patent Claims

Clarity and Specificity

Drafting clear and specific claims is essential. Claims should be written in a way that clearly defines the invention and its scope, avoiding ambiguity and ensuring that the invention is distinguishable from prior art.

Practical Applications

Claims should demonstrate how the invention provides a practical application or solves a specific problem. This helps in establishing the patent eligibility of the invention under the Alice test.

Conclusion

Navigating the complexities of patent claims and the US patent landscape requires a deep understanding of the legal framework, technological trends, and best practices. US Patent 10,016,412, while not specifically detailed here, would need to be analyzed within this broader context. The increasing complexity of patent applications, the importance of integrating abstract ideas into practical applications, and the challenges in patent classification and routing are all critical factors to consider.

Key Takeaways

  • Patent Claims Structure: Independent and dependent claims define the scope of the invention.
  • Patent Eligibility: The Alice test determines whether a claim is directed to a judicial exception and if it transforms into a patent-eligible application.
  • Prior Art and Anticipation: Claims must be novel and non-obvious to be patentable.
  • Technological Advancements: Automation in patent analysis can streamline the process.
  • Practical Utility: Claims must integrate abstract ideas into practical applications to be patent-eligible.
  • Consistency in Analysis: Consistent application of the Alice test is crucial to avoid discrepancies between the USPTO and district courts.

FAQs

Q: What is the purpose of patent claims in a patent application?

A: Patent claims define the scope of protection for an invention, specifying what the applicant seeks to protect.

Q: How has the number of patent applications changed over the years?

A: The number of patent applications has significantly increased, driven by technological innovation and facilitated by advancements in technology.

Q: What is the Alice test, and how is it applied?

A: The Alice test is a two-step framework for determining patent eligibility under 35 U.S.C. § 101. It assesses whether a claim is directed to a judicial exception and if the claim elements transform the nature of the claim into a patent-eligible application.

Q: Why is novelty important in patent law?

A: Novelty is crucial because an invention must be new and non-obvious to be patented. Prior art searches are essential to ensure this.

Q: How do technological advancements impact the patent analysis process?

A: Technological advancements have led to automated systems that can import, parse, and display patent claims, reducing the complexity and volume of information to review.

Sources

  1. USPTO Needs to Improve Oversight and Implementation of Patent Classification and Routing Process. Office of Inspector General, U.S. Department of Commerce.
  2. US20110138338A1 - Patent Claims Analysis System and Method. Google Patents.
  3. Understanding the 2024 USPTO Guidance Update on AI Patent. Mintz.
  4. 2131-Anticipation — Application of 35 U.S.C. 102. United States Patent and Trademark Office.
  5. Alice Patent Eligibility Analysis Divergence Before USPTO and District Court. Foley & Lardner LLP.

More… ↓

⤷  Subscribe

Details for Patent 10,016,412

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Teknika Llc TICE BCG bcg live For Injection 102821 June 21, 1989 ⤷  Subscribe 2021-05-01
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 June 04, 1986 ⤷  Subscribe 2021-05-01
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 ⤷  Subscribe 2021-05-01
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b Injection 103132 ⤷  Subscribe 2021-05-01
Hoffmann-la Roche Inc. ROFERON-A interferon alfa-2a For Injection 103145 June 04, 1986 ⤷  Subscribe 2021-05-01
Iovance Biotherapeutics Manufacturing Llc PROLEUKIN aldesleukin For Injection 103293 May 05, 1992 ⤷  Subscribe 2021-05-01
Partner Therapeutics, Inc. LEUKINE sargramostim For Injection 103362 March 05, 1991 ⤷  Subscribe 2021-05-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.